secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001299130-25-000099
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio Q1 GAAP net loss $426M on restructuring; consumable revenue record, non-GAAP loss narrows
--------------------------------------------------------------------------------

- Revenue $37.2M, down 4% YoY; consumable revenue record $20.1M (+26% YoY).
- GAAP net loss $426.1M ($1.44 EPS) includes $381.8M restructuring charges; non-GAAP net loss $44.4M ($0.15).
- Restructuring plan targets $45-50M annualized non-GAAP opex reduction by end of 2025; focuses on long-read business.
- Shipped 28 Vega and 12 Revio systems (Revio down from 28 YoY); non-GAAP gross margin improved to 40% from 33%.
- Independent investigation of employee allegations may delay Q1 10-Q filing; company sees no material financial impact.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913025000099/0001299130-25-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913025000099/pacb-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001299130-25-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer